Hamilton Wealth LLC Invests $3.86 Million in Guardant Health, Inc. $GH

Hamilton Wealth LLC bought a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 37,784 shares of the company’s stock, valued at approximately $3,859,000.

Other institutional investors also recently bought and sold shares of the company. V Square Quantitative Management LLC purchased a new stake in Guardant Health in the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC acquired a new position in shares of Guardant Health in the 4th quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Guardant Health in the 4th quarter valued at $31,000. Elyxium Wealth LLC purchased a new stake in Guardant Health during the fourth quarter worth $35,000. Finally, Parallel Advisors LLC boosted its holdings in Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after buying an additional 219 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Meghan V. Joyce sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $126.98, for a total transaction of $1,269,800.00. Following the transaction, the director directly owned 11,183 shares in the company, valued at $1,420,017.34. The trade was a 47.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $126.30, for a total value of $12,630,000.00. Following the completion of the sale, the chief executive officer directly owned 2,012,919 shares of the company’s stock, valued at approximately $254,231,669.70. This represents a 4.73% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 449,006 shares of company stock worth $51,148,938. 5.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

GH has been the subject of a number of recent analyst reports. Piper Sandler set a $127.00 price objective on shares of Guardant Health in a report on Thursday, May 21st. Canaccord Genuity Group lifted their price target on Guardant Health from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Barclays upped their price target on Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Stifel Nicolaus increased their price target on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Finally, TD Cowen reissued a “buy” rating on shares of Guardant Health in a report on Thursday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $141.95.

Guardant Health Stock Up 2.1%

Guardant Health stock opened at $131.78 on Friday. The company has a fifty day simple moving average of $106.46 and a 200-day simple moving average of $102.68. The firm has a market capitalization of $17.47 billion, a price-to-earnings ratio of -38.87 and a beta of 1.61. Guardant Health, Inc. has a 52-week low of $40.35 and a 52-week high of $135.00.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.